It could be ENORMOUS, not only for AML patients but in the words...

It could be ENORMOUS, not only for AML patients but in the words Dr Maiti, "practice changing. " Let's keep in mind the worlds premier AML treatment facility, with 9 out of the last 10 FDA approved treatments seeked CHM out.

Dr Maiti said there are 20000 cases in the US alone and the numbers are slowly growing. MD Anderson see's 40 patients a month.

He also mentioned T-ALL leukemia which has 2000 adult cases a year but it's more common in the pediatric population.

The combo with Venetoclax is a possibility in multiple different types of cancers.

Myelodysplasia syndrome is a close cousin of AML, it could also be low hanging fruit.

Any of the other current trails CHM is currently running.

To my knowledge, no NK Cell therapies have been approved by the FDA yet (someone feel free to jump in and correct me), but here's a list of the 6 FDA approved CAR-T therapies and their pricing. I'm guessing that our NK cells will be priced cheaper because they're allogeneic, throw a dart on a price point.


https://hillman.upmc.com/mario-lemieux-center/treatment/car-t-cell-therapy/fda-approved-therapies

1. Abecama- $545000 per patient per treatment

https://www.cadth.ca/sites/default/files/DRR/2021/PG0240%20Abecma%20-%20CADTH%20Final.pdf

2. Breyanzi- $410000

https://www.biopharmadive.com/news/bristol-myers-breyanzi-second-line-fda-approval/626011/

3. Carvykti- $465000 for a one time infusion.

https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-carvykti-multiple-myeloma

4. Kymriah- $475000

https://ashpublications.org/blood/article/142/Supplement%201/6912/506112/Establishing-Costs-for-Commercial-Chimeric-Antigen

5. Tecartus- $533523

https://canjhealthtechnol.ca/index.php/cjht/article/view/pg0219/267

6. Yescarta- $373000

https://www.cancer.gov/news-events/cancer-currents-blog/2017/yescarta-fda-lymphoma